Cargando…
Inhibitory effect of metformin combined with gemcitabine on pancreatic cancer cells in vitro and in vivo
Pancreatic cancer is a malignant digestive system tumor with a particularly poor prognosis, and is the fourth leading cause of cancer-associated mortality in the USA. The anti-diabetic therapeutic agent, metformin (MET) has been demonstrated to exert anti-tumor effects. The present study assessed th...
Autores principales: | Shi, Yuqi, He, Zhilong, Jia, Zhenyu, Xu, Chunfang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042754/ https://www.ncbi.nlm.nih.gov/pubmed/27499118 http://dx.doi.org/10.3892/mmr.2016.5592 |
Ejemplares similares
-
Inhibitory effect of baicalein combined with gemcitabine in human pancreatic cancer cell lines
por: Li, Zhenlei, et al.
Publicado: (2018) -
The Antitumor Activity of Sodium Selenite Alone and in Combination with Gemcitabine in Pancreatic Cancer: An In Vitro and In Vivo Study
por: Doello, Kevin, et al.
Publicado: (2021) -
TM4SF1 Promotes Gemcitabine Resistance of Pancreatic Cancer In Vitro and In Vivo
por: Cao, Jia, et al.
Publicado: (2015) -
Huaier increases the antitumor effect of gemcitabine on pancreatic cancer in vitro and in vivo
por: Chen, Tao, et al.
Publicado: (2021) -
Metformin Inhibits Gemcitabine Induced Apoptosis in Pancreatic Cancer Cell Lines
por: Zechner, Dietmar, et al.
Publicado: (2017)